Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is a world-wide leader in medical aesthetics, with a strong focus on delivering clinically validated solutions for superior skin health. Despite facing regulatory risks and competition from larger operators, the company has shown strong financial performance with consistent beats on revenue and EBITDA, as well as tight control of operating expenses. With a new CEO at the helm and plans to launch new products in the coming years, the company continues to show potential for growth and success.

Bears say

SkinHealth Systems is facing several challenges that may impact its financial performance in the near term. These include their key patents expiring in 2026, ongoing litigation obligations, and intense competition in the rapidly changing skincare market. Additionally, the majority of their sales come from their Hydrafacial platform, making them vulnerable to negative events or declines in demand. Regulatory approval processes and any delays could also significantly impact the company's operations and financial results. Overall, these factors make me cautious about the company's future prospects and lead me to have a negative outlook on their stock.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Jul 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.